ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2469

Associations Between Body Composition Measurements of Obesity and the Radiographic Progression of Hand Osteoarthritis: Data from the Dong-gu Study
Abstract Number: 2470

Low Serum Adiponectin Levels Were Associated with Radiographic Progression of Hand Osteoarthritis in a 6-year Follow-up of the Dong-gu Study
Abstract Number: 2471

Higher Pain and Functional Impairment in Erosive Hand Osteoarthritis Than in Treated Rheumatoid Arthritis: A Comparative Study Between DIGICOD and ESPOIR Cohorts
Abstract Number: 2472

Synovitis and the Risk of Incident Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study
Abstract Number: 2473

A Consensus Based Algorithm to Screen for Lung Disease in Children with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2474

Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience
Abstract Number: 2475

Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders
Abstract Number: 2476

Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score
Abstract Number: 2477

Anifrolumab Normalizes the Type I Interferon Signature in a Cohort of Patients with Type I Interferonopathies
Abstract Number: 2478

Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases
Abstract Number: 2479

Tolerability and Effectiveness of Antifibrotics in Rheumatoid Arthritis-associated Interstitial Lung Disease
Abstract Number: 2480

Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI
Abstract Number: 2481

Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy
Abstract Number: 2482

Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis
Abstract Number: 2483

CD68 and Fibrinoid Necrosis Are Synovial Biomarkers of Severity in Early Rheumatoid Arthritis and Are Associated with a Better Response to Methotrexate: Analysis of the UCLouvain Brussels ERA Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].